Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Topics in Pharmacology   Volumes    Volume 17  Issue 2
The clinical role of soluble guanylyl cyclase stimulators
Bobby D. Nossaman, Edward A. Pankey, Timothy McMahon, Philip J. Kadowitz
Pages: 1 - 12
Number of pages: 12
Current Topics in Pharmacology
Volume 17  Issue 2

Copyright © 2013 Research Trends. All rights reserved

Soluble guanylyl cyclase (sGC) catalyzes cyclic guanosine 3’,5’–monophosphate (cGMP) synthesis. cGMP is involved in relaxation of vascular smooth muscle, modulation of inflammation, inhibition of platelet aggregation, and control of vascular permeability. sGC is the intracellular receptor for nitric oxide (NO) or a nitroso intermediate and has been reported to be the active moiety in traditional organic nitrate therapy used in congestive heart failure and angina pectoris. Low dose organic nitrate therapy has been experimentally used to improve blood flow in shock states from sepsis. Inhaled NO is used in persistent pulmonary hypertension of the newborn and in the intensive care unit for right heart protection following cardiac transplantation. However, NO requires a functional heme-moiety on sGC for activation. The effectiveness of NO is reduced when the heme-moiety is oxidized causing endothelial dysfunction. In this review we discuss animal studies and early clinical trials with agents that stimulate sGC and discuss potential clinical applications in pulmonary hypertension and in perioperative care.
Buy this Article


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms